Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage

Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors. The objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.

NCT Number	NCT06587737
Lead Sponsor	Population Health Research Institute
Conditions	Colchicine, ICH - Intracerebral Hemorrhage, Stroke, Dependence
Enrollment	1,125 participants
Start Date	2026-05-30
Primary Completion	2028-07-30 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-25